This activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with HBV.
Goal Statement
The goal of this program is to improve healthcare providers competency in the understanding the long-term effects and potential liver related complications of chronic liver diseases. The program will also provide education on management options and outcomes of treatment.
Educational Objectives
After completing this
activity, the participants
should be better able to:
•
Differentiate hepatitis B treatment options and outline factors to consider in selecting initial therapy
•
Discuss endpoints for treatment
•
Recognize issues with nucleos(t)ide resistance and discuss management options
Report on a single topic conference on Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Hepatology. 2011 Nov 22. doi: 10.1002/hep.24797. [Epub ahead of print]
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. J Viral Hepat. 2011 Sep;18 Suppl 1:1-16. doi: 10.1111/j.1365-2893.2011.01499.x.
Reduction of liver stiffness by antiviral therapy in chronic hepatitis B Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Kitahara S, Hashimoto S, Kawabe N, Harata M, Nitta Y, Murao M, Nakano T, Shimazaki H, Arima Y, Suzuki K, Yoshioka K. J Gastroenterol. 2011 Aug 6. [Epub ahead of print]
Hepatitis B surface antigen Quantification: Why and How to use it in 2011 - A Core Group Report Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P; for the Good Practice in using sAg in Chronic Hepatitis B Study Group (GPs-CHB Study Group). J Hepatol. 2011 Jun 27. [Epub ahead of print]
Tenofovir nephrotoxicity: 2011 update Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. AIDS Res Treat. 2011;2011:354908. Epub 2011 Jun 7.
Nucleic Acid Testing to Detect HBV Infection in Blood Donors Susan L. Stramer, Ph.D., Ulrike Wend, Daniel Candotti, Ph.D., Gregory A. Foster, B.A., F. Blaine Hollinger, M.D., Roger Y. Dodd, Ph.D., Jean-Pierre Allain, M.D., and Wolfram Gerlich, M.D.
Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Cakalo?lu Y, De?ertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; the HIDIT Study Group. N Engl J Med. 2011 Jan 27;364(4):322-331.
Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC) Franceschi S, Lise M, Trepo C, Berthillon P, Chuang SC, Nieters A, Travis RC, Vermeulen R, Overvad K, Tjonneland AM, Olsen A, Bergmann M, Boeing H, Kaaks R, Becker N, Trichopoulou A, Lagiou P, Bamia C, Palli D, Sieri SA, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Peeters PH, Rodriguez L, Lujan Barroso L, Dorronsoro M, Sanchez MJ, Navarro C, Barricarte Gurrea A, Regner S, Borgquist S, Melin B, Hallmans G, Khaw KT, Wareham NJ, Rinaldi S, Hainaut P, Riboli E, Vineis P. Cancer Epidemiol Biomarkers Prev. 2010 Nov 23. [Epub ahead of print
